OSRH
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Low P/B is a value trap given the operational burn rate.
- P/B ratio of 0.19 is extremely low
- P/S ratio of 6.23 is high for a shrinking company
- No Graham Number available due to lack of earnings
Negative growth trajectory across all primary metrics.
- Revenue growth -58.30%
- Earnings surprise -60%
Long-term destruction of shareholder value.
- 5-year price change of -94.6%
- Consistent failure to meet earnings estimates
Severe insolvency risk due to lack of working capital.
- Low Debt/Equity
- Piotroski F-Score 1/9
- Current Ratio 0.16
- Quick Ratio 0.12
Dividend strength 0/100.
- No dividend paid
- No capacity for dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for OSRH and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
OSRH
OSR Holdings, Inc.
Primary
|
-94.6% | -94.6% | -62.3% | -8.9% | +21.5% | +11.1% |
|
CUE
Cue Biopharma, Inc.
Peer
|
-98.5% | -94.2% | -69.9% | -75.0% | -37.5% | -18.2% |
|
IINN
Inspira Technologies Oxy B.H.N. Ltd.
Peer
|
-91.0% | -65.5% | -31.4% | -62.4% | -26.0% | -11.8% |
|
LPCN
Lipocine Inc.
Peer
|
-90.5% | -50.9% | -23.7% | -23.5% | -67.6% | +22.7% |
|
HBIO
Harvard Bioscience, Inc.
Peer
|
-93.5% | -91.5% | +10.5% | +2.6% | -15.5% | -17.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
OSRH
OSR Holdings, Inc.
|
BEARISH | $18.11M | - | -20.0% | -% | $0.55 | |
|
CUE
Cue Biopharma, Inc.
|
NEUTRAL | $18.38M | - | -121.1% | -96.9% | $0.19 | Compare |
|
IINN
Inspira Technologies Oxy...
|
BEARISH | $18.52M | - | -397.9% | -% | $0.42 | Compare |
|
LPCN
Lipocine Inc.
|
BEARISH | $17.37M | - | -54.3% | -% | $2.38 | Compare |
|
HBIO
Harvard Bioscience, Inc.
|
BEARISH | $19.27M | - | -147.1% | -65.5% | $4.31 | Compare |
Past News Coverage
Recent headlines mentioning OSRH from our newsroom.